Overview
Zevia Q2 net sales rise 10.1% to $44.5 mln, beating expectations
Adjusted EBITDA turns positive, beating analyst estimates, per LSEG data
Net loss narrows to $0.7 mln
Outlook
Zevia expects Q3 2025 net sales of $38 mln to $40 mln
Company expects 2025 adjusted EBITDA to reflect marketing reinvestment
Result Drivers
VOLUME GROWTH - Net sales increase driven by 14.3% volume growth, largely from expanded distribution at Walmart and drug channel
GROSS PROFIT MARGIN - Improvement in gross profit margin due to lower product costs and better inventory management
SELLING EXPENSES - Reduced selling expenses due to savings in freight and warehousing costs from Productivity Initiative
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $44.52 mln | $41.70 mln (5 Analysts) |
Q2 EPS | -$0.01 | ||
Q2 Adjusted EBITDA | Beat | $200,000 | -$2.45 mln (4 Analysts) |
Q2 Gross Profit | $21.69 mln | ||
Q2 Income from Operations | -$1.02 mln | ||
Q2 Operating Expenses | $22.71 mln | ||
Q2 Pretax Profit | -$634,000 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the non-alcoholic beverages peer group is "buy"
Wall Street's median 12-month price target for Zevia PBC is $5.00, about 34.4% above its August 5 closing price of $3.28
Press Release: ID:nBw28pNqda
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.